Main Peptides

Launch Phase: Early access Pricing Sitewide
Sale!
NAD+
NAD+ - Image 2
, , ,

NAD+

Price range: $49.99 through $109.99

Earn up to 110 points.

Complimentary Bacteriostatic Water on orders $300+ (automatically added at checkout)

- +
Add to WishlistRemove from Wishlist

Note: Shipped In Freeze Dried Lyophilized Form – Requires Bacteriostatic Water for Reconstitution (Sold Here)

Vial Size: 10 mL (Can hold up to 10 mL of BAC Water)

FREE shipping on orders $250+
Guaranteed Safe Checkout

NAD+ is a crucial coenzyme found in all living cells, acting as an electron carrier in redox reactions and playing a key role in cellular metabolism. It exists in both oxidized (NAD?) and reduced (NADH) forms. Research has focused on NAD? in relation to mitochondrial function, sirtuin activity, and DNA repair mechanisms. In laboratory settings, NAD? is frequently utilized to study energy homeostasis, enzymatic reactions, and age-related cellular pathways.

Weight .09 kg
Size

100 mg, 250 mg, 500 mg, 750 mg
Shelf Life

24 months
Storage

Lyophilized: freeze at ?20 °C (?4 °F).
Reconstituted: refrigerate at 2–8 °C (35.6–46.4 °F) for up to 14 days; protect from light and avoid freeze–thaw cycles.
Molecular Formula

C21H27N7O14P2
PubChem CID

5892 http://www.pubchem.ncbi.nlm.nih.gov/compound/5892
Disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For research purposes only. Not for human consumption.

You may also like…

  • Sale!

    Epitalon

     Cellular Research Price range: $49.99 through $199.99
  • Sale!

    MOTS-c

     Cellular Research Price range: $39.99 through $59.99
  • Sale!

    Semax

     Cognitive Research Price range: $44.99 through $74.99
  • Sale!

    Glutathione

     Cellular Research Price range: $39.99 through $79.99

Your wishlist is currently empty!

Wishlist
View Wishlist
Research Compound Profile

NAD+

Also known as:Nicotinamide Adenine Dinucleotide · Coenzyme I · Beta-NAD · DPN Category:Anti-Aging · Longevity · Metabolic Clinical Status:Human Trials Ongoing / Supplements Available FDA Status:Not Approved · Available as Supplement

A critical dinucleotide coenzyme present in every living cell, essential for over 500 enzymatic reactions including energy metabolism, DNA repair, and sirtuin activation. NAD+ levels decline significantly with age — by up to 50% between ages 40–60.

Explore the Research ↓
🧬Compound Type

Dinucleotide Coenzyme

📊Molecular Formula

C₂₁H₂₇N₇O₁₄P₂ (663.43 g/mol)

🔬Primary Research Focus

Cellular energy & longevity

🧪Evidence Level

Human trials ongoing · Supplements available

What Is NAD+?

🧠 Simple Explanation

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of your body. Think of it as a helper molecule that your cells need to produce energy, repair DNA, and activate longevity genes called sirtuins. Without enough NAD+, your cells can't function properly.

The problem is that NAD+ levels naturally decline as we age — by up to 50% between ages 40 and 60. This decline is linked to age-related diseases, fatigue, and metabolic dysfunction. Researchers are actively studying ways to restore NAD+ levels.

🔬 Advanced Context

NAD+ (molecular formula: C₂₁H₂₇N₇O₁₄P₂, CAS: 53-84-9) is a dinucleotide composed of nicotinamide and adenine linked by phosphate groups. It serves as an essential cofactor for over 500 enzymatic reactions, functioning primarily as an electron carrier in metabolic redox reactions within mitochondria.

NAD+ is the essential substrate for sirtuins (SIRT1-7), a family of NAD+-dependent deacetylases that regulate aging, inflammation, stress resistance, and metabolism. It also fuels poly-ADP-ribose polymerases (PARPs), enzymes critical for detecting and repairing DNA damage.

A landmark 2022 study of 1,518 participants found that whole blood NAD+ levels average 33.0 μmol/L, with significant decline in the 40–49 age group (β = -1.12), becoming more pronounced after age 60 (β = -2.16). Key precursors under investigation include NMN and NR, while IV NAD+ therapy offers direct delivery with 100% bioavailability.

How It Works

Key biological pathways dependent on NAD+

PATHWAY 01

Sirtuin Activation

NAD+ is the essential substrate for sirtuins (SIRT1-7), a family of NAD+-dependent deacetylases. Without adequate NAD+, sirtuin activity declines, accelerating cellular aging, inflammation, and metabolic dysfunction.

💡 Simple Translation

NAD+ fuels a family of 'longevity enzymes' called sirtuins. When NAD+ levels drop, these enzymes slow down — like a car running low on fuel — and aging processes speed up.

PATHWAY 02

DNA Repair (PARP Activation)

NAD+ fuels poly-ADP-ribose polymerases (PARPs), enzymes critical for detecting and repairing single-strand DNA breaks. PARP1 and PARP2 consume NAD+ to attach ADP-ribose units to damaged DNA sites, recruiting repair machinery.

💡 Simple Translation

Your DNA gets damaged thousands of times daily. NAD+ powers the repair crew (PARP enzymes) that fixes these breaks. Less NAD+ means more unrepaired damage accumulating over time.

PATHWAY 03

Mitochondrial Energy Production

NAD+ is essential for the electron transport chain in mitochondria, acting as an electron carrier in Complex I (NADH dehydrogenase). It participates in the TCA cycle and oxidative phosphorylation, directly driving ATP synthesis.

💡 Simple Translation

Mitochondria are your cells' power plants. NAD+ is the key ingredient they need to convert food into usable energy (ATP). When NAD+ drops, your cells produce less energy — contributing to fatigue.

PATHWAY 04

Cellular Signaling & Immune Regulation

CD38 and CD157 are NAD+ glycohydrolases that consume NAD+ to produce cyclic ADP-ribose (cADPR) for calcium signaling. CD38 activity increases with age, becoming a major driver of NAD+ depletion and immune dysregulation.

💡 Simple Translation

An enzyme called CD38 ramps up as you age, consuming more and more NAD+. This creates a vicious cycle: less NAD+ available for repair and energy, while immune signaling becomes less efficient.

Clinical Development Status

Current position in the research and regulatory pipeline

✓
Preclinical

Laboratory and animal studies. Extensive preclinical data on NAD+ biology, sirtuin activation, and mitochondrial function.

✓
Phase 1

Multiple studies confirmed NAD+ IV infusion safety and oral precursor tolerability.

✓
Phase 2

Several NMN and NR clinical trials completed evaluating metabolic endpoints.

4
Phase 3

Some NR studies have reached this scale; NAD+ IV therapy lacks Phase 3 data.

5
Phase 4

NR (as Niagen) has GRAS status with ongoing safety monitoring.

6
FDA Approved

NAD+ and precursors are available as dietary supplements but not FDA-approved as drugs.

NR (Nicotinamide Riboside) has FDA GRAS status and is available as a supplement. NMN has multiple completed human clinical trials. IV NAD+ therapy is offered in clinical settings but lacks large-scale Phase 3 trial data. Not FDA-approved as a drug for any indication.

What Does the Research Show?

Summary of findings from published human and preclinical studies

📊Key Findings
  • NAD+ levels decline up to 50% between ages 40–60 in human studies
  • 1,518-participant study confirmed age-related NAD+ decline (Yang et al., 2022)
  • Essential cofactor for over 500 enzymatic reactions in cells
  • Activates all 7 sirtuin enzymes (SIRT1-7) linked to longevity
📈Research Milestones
  • NR granted FDA GRAS status as a dietary supplement
  • Multiple completed human clinical trials for NMN (250–1000mg doses)
  • 2019 pilot study confirmed NAD+ elevation via 6-hour IV infusion
  • David Sinclair's Harvard research popularized NAD+ in longevity science
🔬Observed Biological Effects
  • Enhanced mitochondrial function and ATP production in animal models
  • Improved exercise capacity and metabolic function in rodent studies
  • PARP-mediated DNA repair activated by NAD+ availability
  • CD38 identified as major driver of age-related NAD+ depletion
🧪Safety Profile in Studies
  • NR has GRAS (Generally Recognized as Safe) status
  • IV NAD+ generally well-tolerated; side effects rate-dependent
  • Common IV side effects: nausea (40%), flushing (35%), chest tightness (25%)
  • Theoretical cancer concerns with chronic NAD+ elevation remain under study

Published Findings

Peer-reviewed studies with linked sources

StudyModelKey FindingYearSource
Whole blood NAD+ and aging (n=1,518)Human (Cohort)NAD+ levels decline significantly with age; average 33.0 μmol/L; men higher than women (34.5 vs 31.3)2022Frontiers Endocrinol ↗
NAD+ and sirtuins in agingReviewNAD+ is essential substrate for SIRT1-7; decline drives metabolic dysfunction and aging2014Trends Cell Biology ↗
IV NAD+ metabolome pilot studyHuman (n=8)6-hour IV NAD+ infusion significantly elevated plasma NAD+ and metabolites; well-tolerated2019Antioxidants ↗
NAD+ in cardiac health and agingReviewNAD+ depletion linked to cardiac dysfunction; restoration improves mitochondrial function and reduces oxidative stress2021Circulation ↗
NAD+ homeostasis in health & diseaseReviewComprehensive overview of NAD+ biosynthesis, consumption, and therapeutic targeting strategies2020Nature Metabolism ↗
NMN supplementation in humansHuman (RCT)Oral NMN (250mg/day) safely elevated blood NAD+ levels; improved muscle insulin sensitivity2021Science ↗
NR safety and NAD+ elevationHuman (RCT)NR supplementation (1000mg/day) safely increased NAD+ metabolome; well-tolerated over 6 weeks2018Nature Comms ↗
Sirtuins & NAD+ in metabolic diseaseReviewNAD+ repletion through NMN/NR restores sirtuin activity and improves metabolic outcomes in animal models2018Circulation Research ↗

⚠️ Several studies listed are reviews synthesizing existing evidence. Human RCT data is growing but long-term outcomes are still being established.

Research Timeline

Key milestones in NAD+ research and clinical investigation

1906

NAD+ Discovered

Arthur Harden and William John Young first identified NAD+ as a cofactor in yeast fermentation

2000

Sirtuin Connection

Leonard Guarente's lab discovered that sirtuins require NAD+ for their enzymatic activity

2013

NMN Reverses Aging Markers

David Sinclair's Harvard team showed NMN reversed age-related decline in mitochondrial function in mice

2016

CD38 Identified as NAD+ Consumer

CD38 enzyme shown to be a primary driver of age-related NAD+ decline

2018

First NR Human RCT Published

Nature Communications published NR safety and NAD+ elevation data in humans (1000mg/day)

2019

IV NAD+ Pilot Study

6-hour IV NAD+ infusion shown to significantly elevate plasma NAD+ metabolome in humans

2021

NMN Human Trial (Science)

Oral NMN (250mg/day) demonstrated improved muscle insulin sensitivity in prediabetic women

2022

Largest NAD+ Aging Study

1,518-participant cohort confirmed significant age-related NAD+ decline across genders

Delivery Methods Studied in Research

Administration routes evaluated in published studies and clinical practice

Intravenous (IV) Infusion

Direct delivery with 100% bioavailability; typical sessions 250–1000mg over 2–6 hours in clinical settings

Oral NMN Supplementation

Direct NAD+ precursor; 250–1000mg daily; growing human trial data supporting safety and efficacy

Oral NR Supplementation

Converted to NMN then NAD+; 300–1000mg daily; FDA GRAS status; more published clinical trials

Sublingual Administration

Placed under the tongue for faster absorption; bypasses first-pass liver metabolism

Subcutaneous NAD+

Emerging option with less published data; offered in some clinical settings

Dosing Ranges Studied in Research

In published clinical research, NMN has been studied at doses of 250–1000mg daily orally, while NR has been evaluated at 300–1000mg daily. IV NAD+ therapy typically delivers 250–1000mg per session over 2–6 hours. A 2019 pilot study evaluated 6-hour IV infusions in healthy adults.

⚠️ These figures are presented for scientific reference only. IV NAD+ should only be administered under medical supervision. Optimal dosing protocols are still being established through ongoing clinical trials.

Molecular Profile

Physicochemical characteristics and storage parameters

Molecular Weight

663.43 g/mol

Structure Type

Dinucleotide Coenzyme

CAS Number

53-84-9

Molecular Formula

C₂₁H₂₇N₇O₁₄P₂

Components

Nicotinamide + Adenine + Ribose + Phosphate

Solubility

Freely soluble in water

Storage (Powder)

-20°C, protected from light

Appearance

White to off-white powder

Reference: PubChem CID 5893

Research Applications

Areas of active investigation in peer-reviewed literature

Investigated in sirtuin-mediated longevity pathways (SIRT1-7 activation and cellular aging)

Studied in mitochondrial function and ATP production via electron transport chain

Explored in PARP-mediated DNA repair and genomic integrity maintenance

Examined in age-related metabolic dysfunction and insulin sensitivity

Evaluated in cardiac health and NAD+ depletion in cardiovascular disease models

Assessed in neurodegeneration and cognitive decline linked to NAD+ loss

Investigated in CD38-driven NAD+ consumption and immune cell regulation

Studied alongside NMN and NR precursors for NAD+ restoration strategies

Formulation & Preparation

Understanding NAD+ delivery formats and handling requirements

💊

Multiple Delivery Forms

NAD+ is available as lyophilized powder for IV/subcutaneous use and as oral capsules (NMN, NR precursors). IV solutions require clinical preparation, while oral forms are available as dietary supplements.

❄️

Stability & Storage

Lyophilized NAD+ powder should be stored at -20°C, protected from light and moisture. Once reconstituted, solutions should be used promptly and refrigerated. NAD+ is sensitive to heat, light, and pH extremes.

📅

Shelf Life Considerations

Dry powder form maintains potency at -20°C for extended periods. Reconstituted solutions have limited stability and should be used within hours for IV administration. Oral supplements follow standard supplement shelf life guidelines.

🔬

IV Preparation Standards

IV NAD+ is prepared in clinical settings using sterile technique. Infusion rates are carefully controlled — slower rates (2–6 hours for 500–1000mg) significantly reduce nausea and discomfort.

✅

Quality Verification

Research-grade NAD+ is verified via HPLC for purity and mass spectrometry for identity. NR supplements carrying GRAS status undergo additional regulatory oversight for safety and quality.

Transparency & Quality Verification

Analytical standards applied to research-grade NAD+ materials

🧪

Third-Party Analytical Testing

Independent laboratories perform comprehensive analysis on each production batch, ensuring unbiased verification of compound identity and purity.

📊

Purity Verification (HPLC)

High-Performance Liquid Chromatography confirms NAD+ purity levels, typically targeting ≥98% for research-grade material and clinical-use preparations.

🔬

Identity Confirmation (Mass Spectrometry)

Mass spectrometry validates molecular weight (663.43 g/mol) and structural identity, confirming the compound matches its expected dinucleotide profile.

📋

Batch-Specific Certificates of Analysis

Each lot is accompanied by a unique COA detailing purity percentage, lot number, test date, labeled vs. actual content, and testing laboratory.

📁

Regulatory Compliance

NR (Nicotinamide Riboside) supplements carry FDA GRAS status. IV NAD+ preparations follow clinical compounding standards. All analytical results are available for review.

🌡️

Storage & Cold-Chain Integrity

Temperature monitoring ensures proper storage at -20°C for powder and refrigeration for reconstituted solutions. Proper handling preserves compound stability and efficacy.

Frequently Asked Questions

Common questions about NAD+ research and supplementation

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every cell of your body. It's essential for over 500 enzymatic reactions, including energy production in mitochondria, DNA repair via PARPs, and activation of longevity-related sirtuins (SIRT1-7). NAD+ levels naturally decline with age — by up to 50% between ages 40–60 — contributing to metabolic dysfunction and age-related conditions.
IV NAD+ delivers the coenzyme directly into your bloodstream with 100% bioavailability, bypassing digestive metabolism. Oral precursors like NMN and NR must be absorbed and converted into NAD+ through enzymatic pathways, with variable efficiency. IV administration provides immediate cellular access, though it requires clinical administration and sessions typically last 2–6 hours.
A 2022 study of 1,518 participants found that blood NAD+ levels significantly decline with age, particularly in men. The average whole blood NAD+ was 33.0 μmol/L, with men showing higher levels than women (34.5 vs 31.3 μmol/L). Significant decline was observed in the 40–49 age group, becoming more pronounced after age 60. Animal studies show NMN can reverse age-related mitochondrial dysfunction.
NAD+ infusions typically last 2–6 hours depending on the dose (250–1000mg). Common experiences include temporary nausea (~40%), flushing (~35%), chest tightness (~25%), or cramping — these are usually managed by slowing the infusion rate. Most people feel energized after the session. Side effects generally diminish with subsequent treatments as tolerance develops.
NMN (Nicotinamide Mononucleotide) is a direct precursor to NAD+, typically dosed at 250–1000mg daily with growing human trial data. NR (Nicotinamide Riboside) is converted to NMN first, then to NAD+, typically dosed at 300–1000mg daily. NR has more published clinical trials and FDA GRAS status. Both have shown the ability to safely elevate NAD+ levels in humans.
NR has FDA GRAS (Generally Recognized as Safe) status. IV NAD+ is generally well-tolerated, with side effects primarily related to infusion rate rather than total dose. Oral NMN and NR are well-tolerated with rare mild side effects (nausea, diarrhea). There are theoretical concerns about chronic NAD+ elevation potentially supporting tumor growth, as cancer cells also rely on NAD+ — this remains under active study.
Research shows NAD+ levels can decline by approximately 50% between ages 40 and 60. The 2022 Yang et al. study of 1,518 participants found significant decline starting in the 40–49 age group (β = -1.12), becoming more pronounced after age 60 (β = -2.16). This decline is driven by increased activity of NAD+-consuming enzymes like CD38 and PARPs, combined with reduced biosynthesis efficiency.
NAD+ itself is not well-absorbed orally, which is why precursors like NMN and NR are used as oral supplements. These precursors are absorbed in the gut and converted to NAD+ through enzymatic pathways. Both NMN and NR have demonstrated the ability to elevate blood NAD+ levels in human trials. Sublingual NAD+ is also available, though with less published data.
NAD+ is not FDA-approved as a drug for any specific medical indication. However, NR (Nicotinamide Riboside, sold as Niagen) has received FDA GRAS status and is available as a dietary supplement. NMN is also available as a supplement. IV NAD+ therapy is offered in clinical settings under medical supervision but has not undergone the full FDA drug approval process.
Lyophilized (powder) NAD+ should be stored at -20°C, protected from light and moisture. Once reconstituted, solutions should be used promptly and kept refrigerated if not used immediately. NAD+ is sensitive to heat, light, and pH extremes. Oral supplements (NMN, NR) should be stored according to manufacturer guidelines, typically at room temperature in a cool, dry place.
While NAD+ itself is not a peptide, several peptides interact with NAD+ metabolism. MOTS-c is a mitochondrial-derived peptide that may affect NAD+ utilization. Humanin is another mitochondrial peptide with metabolic effects. Epitalon may influence cellular energy pathways indirectly. SS-31 targets mitochondrial function directly. These are all being studied for their roles in aging and metabolic health.
NAD+ research has focused on age-related decline, metabolic dysfunction, and cellular energy support. Those interested typically include adults over 40 concerned about aging, individuals seeking mitochondrial function support, and those looking to complement healthy lifestyle practices. NAD+ therapy should be discussed with a healthcare provider to determine appropriateness for individual circumstances.

Sources & References

Peer-reviewed publications and reference materials cited on this page

Association of Human Whole Blood NAD+ Contents With Aging ↗

Yang F, Deng X, Yu Y, et al. · Frontiers in Endocrinology (2022) · DOI: 10.3389/fendo.2022.829658

NAD+ and Sirtuins in Aging and Disease ↗

Imai S, Guarente L · Trends in Cell Biology (2014)

A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+ ↗

Grant R, et al. · Antioxidants (2019)

NAD+ Metabolism in Cardiac Health, Aging, and Disease ↗

Abdellatif M, et al. · Circulation (2021)

NAD+ Homeostasis in Health and Disease ↗

Katsyuba E, et al. · Nature Metabolism (2020)

Sirtuins and NAD+ in the Development and Treatment of Metabolic and Cardiovascular Diseases ↗

Kane AE, Sinclair DA · Circulation Research (2018)

Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women ↗

Yoshino M, et al. · Science (2021)

Chronic Nicotinamide Riboside Supplementation is Well-Tolerated and Elevates NAD+ in Healthy Middle-Aged and Older Adults ↗

Martens CR, et al. · Nature Communications (2018)

Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence ↗

Rajman L, Chwalek K, Sinclair DA · Cell Metabolism (2018)

⚠️ Important Notice

For educational and research reference purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease.

All information presented on this page is derived from peer-reviewed literature and is provided exclusively for educational and scientific reference purposes. Nothing on this page constitutes medical advice, personal recommendations, or encouragement of any kind. Consult a qualified healthcare provider before making any decisions about NAD+ supplementation or therapy.

Search
Shopping Cart
NAD+
100 mg
250 mg
500 mg
750 mg
Price range: $49.99 through $109.99
−
+